...
首页> 外文期刊>Chinese Journal of Contemporary Neurology and Neurosurgery >Application of individualized therapy based on molecular classification in the treatment of medulloblastoma in children
【24h】

Application of individualized therapy based on molecular classification in the treatment of medulloblastoma in children

机译:个体化治疗在分子分类中的应用在儿童中髓母细胞瘤的治疗中

获取原文
           

摘要

Abstract Objective To explore the clinical efficacy of individualized therapy based on molecular classification in the treatment of medulloblastoma in children. Methods The clinical data of 23 children with medulloblastoma confirmed by pathology after surgery from December 2017 to December 2019 were analyzed retrospectively. The 5 ? year survival rate risk was stratified according to tumor molecular classification, and individualized chemoradiotherapy were given. Chemoradiotherapy response, postoperative complications and tumor recurrence were recorded. Results There were 23 cases of medulloblastoma. The tumor molecular genes were classified as WNT type 3 cases, SHH type 7 cases, Group3 type 5 cases and Group4 type 8 cases. The patients were divided into 4 groups according to the results of molecular classification as risk factors: low risk group (n = 5), standard risk group (n = 8), high risk group (n = 5) and very high risk group (n = 5). Total tumor resection was performed in 20 cases, subtotal resection in 3 cases. Three cases with hydrocephalus aggravated after surgery, 2 cases with cerebellar silence, 3 cases with cough paralysis and other neurological symptoms, which were relieved after symptomatic treatment. Individualized treatment (radiotherapy chemotherapy) was carried out according to the risk stratification. The mean postoperative follow ? up period was (15.15 ± 3.45) months. The tolerance of radiotherapy and chemotherapy in the low risk group and the standard risk group was strong, and no tumor recurrence was observed. After radiotherapy and chemotherapy, the high risk group and the very high risk group showed obvious bone marrow suppression and gastrointestinal symptoms, which were relieved after symptomatic treatment, and there were 2 cases in the high risk group and 3 cases in the very high risk group occuring tumor recurrence. Conclusions The risk stratification based on molecular classification is more accurate, and the individualized therapy could avoid excessive or insufficient clinical treatment, which is worthy of clinical promotion.
机译:摘要目的探讨个性化治疗基于分子分类治疗儿童Medulloblastoma的临床疗效。方法回顾性分析2017年12月至2019年12月的病理学后23例患有Medulloblastoma的临床资料。 5?年份存活率风险根据肿瘤分子分类分层,并给出个性化的化学疗法。记录了化学疗法反应,术后并发症和肿瘤复发。结果23例Medulloblastoma。肿瘤分子基因被归类为WNT型3例,SHH型7例,第3型患者和第4型患者8例。将患者分为4组,根据分子分类的结果作为风险因素:低风险组(n = 5),标准风险组(n = 8),高风险组(n = 5)和非常高的风险组( n = 5)。总肿瘤切除在20例,畸形切除3例。手术后脑药加剧了三种病例,2例患有小脑沉默,3例咳嗽瘫痪和其他神经症状,其症状治疗后得到缓解。根据风险分层进行个性化治疗(放射疗法化疗)。术后平均遵循? UP期间是(15.15±3.45)个月。放射疗法和化疗在低风险组和标准风险组中的耐受性强烈,并且没有观察到肿瘤复发。放射治疗和化疗后,高风险组和非常高的风险组显示出明显的骨髓抑制和胃肠道症状,症状治疗后缓解,高风险组中有2例,高风险群体3例发生肿瘤复发。结论基于分子分类的风险分层更准确,个体化治疗可以避免过度或不足的临床治疗,这是值得临床促进的。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号